Rifampin Capsule Shortage: Supply Updates and Manufacturer Discontinuations

Source: FDA · United States

According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.

Certain presentations of Rifampin capsules are currently unavailable due to manufacturing discontinuations, though specific package sizes remain available from Epic Pharma, LLC.

What this FDA drug-shortage notice tells you, and what most readers miss

This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.

For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Rifampin) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.

What's in Shortage

Rifampin capsules, an anti-infective medication also known by the brand name RIFAMPIN, are currently listed in a shortage status. This affects both 150 mg and 300 mg dosage forms. While some specific package sizes remain available, several others have been discontinued by the manufacturer. This shortage has been active since December 2021 and was most recently updated in February 2026.

Which Manufacturers Are Affected

Epic Pharma, LLC

  • Status: Limited Availability / Partial Discontinuation
  • Available Presentations:
    • Rifampin, Capsule, 300 mg (NDC 42806-799-60)
    • Rifampin, Capsule, 150 mg (NDC 42806-801-30)
  • Unavailable Presentations (Discontinued):
    • Rifampin, Capsule, 300 mg (NDC 42806-799-30)
    • Rifampin, Capsule, 300 mg (NDC 42806-799-05)
    • Rifampin, Capsule, 300 mg (NDC 42806-799-01)
    • Rifampin, Capsule, 150 mg (NDC 42806-801-01)
  • Contact Information: (718) 276-8600 ext. 3

Why There's a Shortage

The current shortage is due to the discontinuation of the manufacture of specific drug presentations by Epic Pharma, LLC.

What Patients Should Do

If you are currently prescribed Rifampin, it is important to check your supply and speak with your healthcare provider or pharmacist. Because some package sizes (NDCs) are still available while others are discontinued, your pharmacy may need to source a different package size than what you have previously received.

  • Consult your healthcare provider: Discuss your treatment plan and ensure you have a continuous supply of medication.
  • Speak with your pharmacist: They can check current stock levels and verify which presentations are currently in stock.
  • Contact the manufacturer: For specific supply questions, you can reach Epic Pharma, LLC at (718) 276-8600 ext. 3.

Disclaimer: Patients should always consult their healthcare provider regarding their treatment and any potential changes to their medication regimen. This article is for informational purposes only and does not constitute medical advice.

Source

Information provided by the FDA Drug Shortage Database. Initial Posting Date: 12/22/2021 Last Updated: 02/04/2026

Original source: FDA Official Notice ↗

All Drug Shortages →

Frequently Asked Questions

Common questions about this FDA drug-shortage notice.

What is this FDA drug-shortage notice about?
Certain presentations of Rifampin capsules are currently unavailable due to manufacturing discontinuations, though specific package sizes remain available from Epic Pharma, LLC.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "medium" severity. Stay informed and follow agency guidance.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more Drug Shortages updates?
Browse the full Drug Shortages feed on Areazine at areazine.com/drug-shortages/ for the latest updates from FDA and other agencies.